Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito, the mosquitoes that alos spread dengue and chikungunya viruses.

Phase I Human Trial of Zika Vaccine Approved

"We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers," said Dr. J. Joseph Kim, Inovio Pharmaceuticals, Inc.'s president and CEO. "We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year."

  • Jun 21, 2016

Inovio Pharmaceuticals, Inc. (Plymouth Meeting, Pa., and San Diego, Calif.) and GeneOne Life Science, Inc. (Seoul, South Korea) have received approval to initiate a phase I human trial to evaluate Inovio's Zika DNA vaccine to prevent infection from the virus, the companies announced June 20. In preclinical testing, the synthetic vaccine "induced robust antibody and T cell responses in small and large animal models, demonstrating the product's potential to prevent infection from this harmful pathogen in humans," they reported.

Their phase I, open-label, dose-ranging study with 40 healthy subjects will evaluate vaccine's safety, tolerability, and immunogenicity.

"We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers. As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus; the incidences of viral infection and medical conditions caused by the virus are expanding, not contracting. We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year," said Dr. J. Joseph Kim, Inovio's president and CEO.

"It is an honor for our company to help usher this Zika vaccine through the clinical and regulatory process. We look forward to conducting this trial with the goal of achieving products to combat this dreaded virus," agreed Young K. Park, GeneOne's president and CEO.

The two companies are developing the Zika vaccine, GLS-5700, with academic collaborators from the United States and Canada with whom they previously collaborated to advance Inovio's Ebola and MERS vaccines into clinical development.

Currently there is no vaccine or therapy for the Zika virus.

Product Showcase

  • The MGC Simple Plus

    The MGC Simple Plus is a simple-to-use, portable multi gas detector that runs continuously for three years without being recharged or routinely calibrated after its initial charge and calibration during manufacturing. The detector reliably tests a worksite’s atmosphere for hydrogen sulfide, carbon monoxide, oxygen and combustible gases (LEL). Its durability enables the detector to withstand the harshest treatment and environments, hence earning it an IP 68 rating. The MGC Simple Plus is also compatible with a variety of accessories, such as the GCT External Pump. Visit gascliptech.com for more information. Read More

  • Full Line of Defense Against Combustible Dust Nilfisk

    Nilfisk provides a comprehensive range of industrial vacuums meticulously crafted to adhere to NFPA 652 housekeeping standards, essential for gathering combustible dust in Class I, Group D, and Class II, Groups E, F & G environments or non-classified settings. Our pneumatic vacuums are meticulously engineered to fulfill safety criteria for deployment in hazardous surroundings. Leveraging advanced filtration technology, Nilfisk ensures the secure capture of combustible materials scattered throughout your facility, ranging from fuels, solvents, and metal dust to flour, sugar, and pharmaceutical powders. Read More

  • SwabTek® Cannabis Test Kit

    The SwabTek® Cannabis Test Kit is a single-use spot test designed for use in screening for cannabis compounds in any sample type or on any surface. The test is capable of identifying the presumed presence of cannabinoids in very small quantities, with a level of detection as little as 6 μg in mass. Learn more about the SwabTek® Cannabis Test Kit and the rest of SwabTek surface drug testing solutions through the webinar titled "Everything You Want To Know About Surface Testing" Read More

Featured

Most   Popular

Artificial Intelligence